A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD) (AC4115321)

Inclusion Criteria:

• Outpatient
• A signed and dated written informed consent prior to study participation.
• Male or female adults.
• 40 to 80 years of age at Visit 1
• Diagnosis of COPD
• Current or former cigarette smokers with a history of cigarette smoking of greater than or equal to 10 pack-years
• Post-albuterol forced expiratory volume in 1 second (FEV1)/ forced vital capacity (FVC)<0.70 and post albuterol FEV1 of greater than or equal to 35% and less than or equal to 70% of predicted normal values

Exclusion Criteria:

• Women who are pregnant or lactating or are planning on becoming pregnant during the study.
• A current diagnosis of asthma
• Known alpha-1 antitrypsin deficiency, active lung infections (such as tuberculosis), and lung cancer
• Other significant respiratory conditions in addition to COPD
• Other diseases that are uncontrolled including cancer in remission for less than 5 years
• Chest x-ray or CT scan with clinically significant abnormalities not believed to be due to the presence of COPD
• Hypersensitivity to any anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate
• A medical condition that contraindicates study participation or use of an inhaled anticholinergic
• Hospitalization for COPD or pneumonia within 12 weeks of Visit 1
• Any previous lung resection surgery
• A body mass index (BMI) value of >35 kilogram (kg)/meter squared (m2)
• An abnormal and significant electrocardiogram finding at Visit 1
• Significantly abnormal finding from clinical chemistry or haematology tests at Visit 1.
• A positive Hepatitis B surface antigen or positive Hepatitis C antibody
• Medically unable to withhold albuterol (salbutamol) for the 6 hour period prior to study visits
• Use of depot corticosteroids within 12 weeks of Visit 1
• Use of oral or parenteral corticosteroids or antibiotics for lower respiratory tract infection within 6 weeks of Visit 1
• Use of long-acting beta-agonist (LABA)/inhaled corticosteroid (ICS) product if LABA/ICS therapy is discontinued within 30 days of Visit 1
• Use of ICS at a dose of >1000mcg/day of fluticasone propionate or equivalent within 30 days of Visit 1
• Initiation or discontinuation of ICS within 30 days of Visit 1
• Use of tiotropium or phosphodiesterase 4 inhibitors within 14 days of Visit 1
• Use of theophyllines, oral leukotriene inhibitors, long-acting oral beta-agonists, or inhaled long-acting beta-agonists within 48 hours of Visit 1
• Short-acting oral beta-agonists within 12 hours of Visit 1
• Use of LABA/ICS combination products only if discontinuing LABA therapy and switching to ICS monotherapy within 48 hours of Visit 1 for the LABA component
• Use of sodium cromoglycate or nedocromil sodium within 24 hours of Visit 1
• Use of inhaled short-acting beta-agonists, inhaled short-acting anticholinergics, or inhaled short-acting anticholinergic/short-acting beta-agonist combination products within 6 hours of Visit 1
• Use of any other investigational medication within 30 days or 5 drug half-lives (whichever is longer)
• Oxygen therapy prescribed for greater than 12 hours a day
• Regular use (prescribed for use every day, not for as-needed use) of short-acting bronchodilators
• Use of continuous positive airway pressure (CPAP), nocturnal positive pressure or non-invasive positive pressure ventilation (NIPPV), including use for sleep apnea.
• Acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1
• A known or suspected history of alcohol or drug abuse within 2 years prior to Visit 1
• Anyone affiliated with investigator site
• Previous use of GSK573719 or GSK53719/GW642444